Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
→ The South Korean biosimilar player Samsung Bioepis has launched a copycat of Remicade on the US market at a 35% discount to J&J’s list price for that therapy. Remicade is J&J’s top earner, and the pharma giant has filed suit to try and stop Samsung’s rival for being introduced. There’s been considerable speculation on how generic versions of biologics could impact pricing.
→ The FDA approved a subcutaneous formulation of Benlysta for lupus, making it possible for patients to switch from an IV version of the GSK drug to a self-administered shot.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.